{"name":"Jiangsu Simcere Pharmaceutical Co., Ltd.","slug":"jiangsu-simcere-pharmaceutical-co-ltd","ticker":"","exchange":"","domain":"jiangsusimcere.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":10,"colorKey":"immunology","drugs":[{"name":"Endostar continuous intravenous infusion","genericName":"Endostar continuous intravenous infusion","slug":"endostar-continuous-intravenous-infusion","indication":"Non-small cell lung cancer (NSCLC)","status":"phase_3"},{"name":"Endostar routine intravenous infusion","genericName":"Endostar routine intravenous infusion","slug":"endostar-routine-intravenous-infusion","indication":"Non-small cell lung cancer (NSCLC)","status":"phase_3"},{"name":"Fluorouracil Implants","genericName":"Fluorouracil Implants","slug":"fluorouracil-implants","indication":"Adjuvant treatment of resectable rectal cancer","status":"phase_2"},{"name":"Bendamustine hydrochloride injection","genericName":"Bendamustine hydrochloride injection","slug":"bendamustine-hydrochloride-injection","indication":"Chronic lymphocytic leukemia (CLL)","status":"phase_3"},{"name":"Docetaxel Polymeric Micelles for Injection","genericName":"Docetaxel Polymeric Micelles for Injection","slug":"docetaxel-polymeric-micelles-for-injection","indication":"Non-small cell lung cancer","status":"phase_2"},{"name":"ENDOSTAR，cisplatin","genericName":"ENDOSTAR，cisplatin","slug":"endostar-cisplatin","indication":"Non-small cell lung cancer (in combination with cisplatin)","status":"phase_3"},{"name":"Placebo , cisplatin","genericName":"Placebo , cisplatin","slug":"placebo-cisplatin","indication":"Various solid tumors (specific indication in this Phase 3 trial unknown without additional context)","status":"phase_3"},{"name":"Suvemcitug injection, trifluridine/tipiracil tablets","genericName":"Suvemcitug injection, trifluridine/tipiracil tablets","slug":"suvemcitug-injection-trifluridine-tipiracil-tablets","indication":"Metastatic colorectal cancer (previously treated)","status":"phase_3"},{"name":"Trilaciclib, carboplatin, etoposide，or Topotecan","genericName":"Trilaciclib, carboplatin, etoposide，or Topotecan","slug":"trilaciclib-carboplatin-etoposide-or-topotecan","indication":"Small cell lung cancer","status":"phase_3"},{"name":"placebo, carboplatin, etoposide，or Topotecan","genericName":"placebo, carboplatin, etoposide，or Topotecan","slug":"placebo-carboplatin-etoposide-or-topotecan","indication":"Advanced ovarian cancer","status":"phase_3"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":7,"colorKey":"oncology","drugs":[{"name":"SIM0270","genericName":"SIM0270","slug":"sim0270","indication":"Other","status":"phase_3"},{"name":"Compound Edaravone Injection","genericName":"Compound Edaravone Injection","slug":"compound-edaravone-injection","indication":"Acute ischemic stroke","status":"phase_3"},{"name":"SIM0237","genericName":"SIM0237","slug":"sim0237","indication":"Other","status":"phase_1"},{"name":"Sevacizumab","genericName":"Sevacizumab","slug":"sevacizumab","indication":"Other","status":"phase_1"},{"name":"SIM0388","genericName":"SIM0388","slug":"sim0388","indication":"Other","status":"phase_1"},{"name":"SIM0811","genericName":"SIM0811","slug":"sim0811","indication":"Other","status":"phase_1"},{"name":"SSD8432 dose 10~12 and ritonavir","genericName":"SSD8432 dose 10~12 and ritonavir","slug":"ssd8432-dose-10-12-and-ritonavir","indication":"Other","status":"phase_1"}]},{"name":"Cardiovascular","slug":"cardiovascular","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"cardiovascular","drugs":[{"name":"Levamlodipine besylate","genericName":"Levamlodipine besylate","slug":"levamlodipine-besylate","indication":"Hypertension","status":"marketed"}]}],"pipeline":[{"name":"SIM0270","genericName":"SIM0270","slug":"sim0270","phase":"phase_3","mechanism":"SIM0270 is a small molecule inhibitor targeting a specific molecular pathway involved in disease pathogenesis, though the exact mechanism requires further clarification.","indications":[],"catalyst":""},{"name":"Compound Edaravone Injection","genericName":"Compound Edaravone Injection","slug":"compound-edaravone-injection","phase":"phase_3","mechanism":"Edaravone is a free radical scavenger that reduces oxidative stress and neuronal damage by neutralizing hydroxyl radicals and other reactive oxygen species.","indications":["Acute ischemic stroke","Amyotrophic lateral sclerosis (ALS)"],"catalyst":""},{"name":"Endostar continuous intravenous infusion","genericName":"Endostar continuous intravenous infusion","slug":"endostar-continuous-intravenous-infusion","phase":"phase_3","mechanism":"Endostar is a recombinant human endostatin that inhibits angiogenesis by blocking new blood vessel formation in tumors.","indications":["Non-small cell lung cancer (NSCLC)","Other solid tumors (in development)"],"catalyst":""},{"name":"Endostar routine intravenous infusion","genericName":"Endostar routine intravenous infusion","slug":"endostar-routine-intravenous-infusion","phase":"phase_3","mechanism":"Endostar is a recombinant human endostatin that inhibits angiogenesis by blocking new blood vessel formation in tumors.","indications":["Non-small cell lung cancer (NSCLC)","Other solid tumors (in combination with chemotherapy)"],"catalyst":""},{"name":"Fluorouracil Implants","genericName":"Fluorouracil Implants","slug":"fluorouracil-implants","phase":"phase_2","mechanism":"Fluorouracil implants work by releasing fluorouracil, a thymidylate synthase inhibitor, which interferes with DNA synthesis and function.","indications":["Adjuvant treatment of resectable rectal cancer"],"catalyst":""},{"name":"SIM0237","genericName":"SIM0237","slug":"sim0237","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Sevacizumab","genericName":"Sevacizumab","slug":"sevacizumab","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Bendamustine hydrochloride injection","genericName":"Bendamustine hydrochloride injection","slug":"bendamustine-hydrochloride-injection","phase":"phase_3","mechanism":"Bendamustine is an alkylating agent that cross-links DNA strands, causing cell death in rapidly dividing cancer cells.","indications":["Chronic lymphocytic leukemia (CLL)","Non-Hodgkin's lymphoma (NHL)","Hodgkin's lymphoma"],"catalyst":""},{"name":"Docetaxel Polymeric Micelles for Injection","genericName":"Docetaxel Polymeric Micelles for Injection","slug":"docetaxel-polymeric-micelles-for-injection","phase":"phase_2","mechanism":"Docetaxel inhibits microtubule dynamics by stabilizing microtubules and preventing their depolymerization.","indications":["Non-small cell lung cancer","Breast cancer","Prostate cancer"],"catalyst":""},{"name":"ENDOSTAR，cisplatin","genericName":"ENDOSTAR，cisplatin","slug":"endostar-cisplatin","phase":"phase_3","mechanism":"Endostar is a recombinant human endostatin that inhibits angiogenesis by blocking new blood vessel formation, used in combination with cisplatin chemotherapy to treat solid tumors.","indications":["Non-small cell lung cancer (in combination with cisplatin)","Advanced solid tumors (Phase 3 development)"],"catalyst":""},{"name":"Levamlodipine besylate","genericName":"Levamlodipine besylate","slug":"levamlodipine-besylate","phase":"marketed","mechanism":"Levamlodipine besylate is the active L-enantiomer of amlodipine that blocks L-type calcium channels in vascular smooth muscle and cardiac tissue, causing vasodilation and reducing blood pressure.","indications":["Hypertension","Angina pectoris"],"catalyst":""},{"name":"Placebo , cisplatin","genericName":"Placebo , cisplatin","slug":"placebo-cisplatin","phase":"phase_3","mechanism":"Cisplatin is a platinum-based chemotherapy agent that forms DNA crosslinks to inhibit cancer cell replication and induce apoptosis.","indications":["Various solid tumors (specific indication in this Phase 3 trial unknown without additional context)"],"catalyst":""},{"name":"SIM0388","genericName":"SIM0388","slug":"sim0388","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"SIM0811","genericName":"SIM0811","slug":"sim0811","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"SSD8432 dose 10~12 and ritonavir","genericName":"SSD8432 dose 10~12 and ritonavir","slug":"ssd8432-dose-10-12-and-ritonavir","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Suvemcitug injection, trifluridine/tipiracil tablets","genericName":"Suvemcitug injection, trifluridine/tipiracil tablets","slug":"suvemcitug-injection-trifluridine-tipiracil-tablets","phase":"phase_3","mechanism":"Trifluridine/tipiracil is a nucleoside analog combination that inhibits thymidylate synthase and incorporates into DNA to induce apoptosis in cancer cells.","indications":["Metastatic colorectal cancer (previously treated)","Gastric cancer (advanced or metastatic)"],"catalyst":""},{"name":"Trilaciclib, carboplatin, etoposide，or Topotecan","genericName":"Trilaciclib, carboplatin, etoposide，or Topotecan","slug":"trilaciclib-carboplatin-etoposide-or-topotecan","phase":"phase_3","mechanism":"Trilaciclib is a CDK4/6 inhibitor that blocks cell cycle progression.","indications":["Small cell lung cancer","Extensive-stage small cell lung cancer"],"catalyst":""},{"name":"placebo, carboplatin, etoposide，or Topotecan","genericName":"placebo, carboplatin, etoposide，or Topotecan","slug":"placebo-carboplatin-etoposide-or-topotecan","phase":"phase_3","mechanism":"Carboplatin is a platinum-based chemotherapy drug that works by crosslinking DNA, thereby inhibiting DNA replication and transcription.","indications":["Advanced ovarian cancer","Small cell lung cancer","Non-small cell lung cancer","Testicular cancer","Urothelial cancer"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMitgFBVV95cUxQSW1JZ2RPb3E0TkRYSUh1Y0tJQ1VzVE9nTjdIbzdpdXNvaWU1X1VkN3pSalRxVTlPNEw1YTV1TzAzVHlhc1BXSWFTM2U1LWdMaWdFM19lakNjVmZIVWdyTThxN2xvdWtHVkJkWVBCNjVWSF9QUXJwZDUydlFrdFNzTFNFdkVxOTRZbEVST084UlVoSWJKNnRjYWRBZGZkYmdsanJScXBNMG90Z1hKWk5Hekk2WG5RZw?oc=5","date":"2026-03-25","type":"deal","source":"富途牛牛","summary":"Simcere Pharmaceutical (02096.HK) subsidiary acquired 100% equity of Shanghai Simcere Diagnostics Technology for RMB 30.76 million. - 富途牛牛","headline":"Simcere Pharmaceutical (02096.HK) subsidiary acquired 100% equity of Shanghai Simcere Diagnostics Technology for RMB 30.","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi5gFBVV95cUxPU1RUQVdCc2lDZDVqcGNIeTRsRWt0ZnlOQ0NZNF95M00xcHVPRW14QnM2clhJOTJtVXM2ZVpIWk5mNEJINmV0NXpOY3dwSWRxSHh4Zy1FMmgtbTF5NjZEYWVXU3F4cS1PV09xZ29qcXI2VzFMbWZEaThwRFJBUjNLNjRTYThOaDMxdDc4ZkIzT25sbHo2SDgtazNJdFdCdzllc3pCMGhNaHlYS2Q1N05jam92TDdzelVJWk5qODAzMHNDODhZTmRQUmxJRlFoQVJQdDNKcVVEY2xRdUhFNjUtT3hJQThpdw?oc=5","date":"2026-01-27","type":"deal","source":"Reuters","summary":"Boehringer Ingelheim in deal with China's Simcere Pharma to license IBD drug candidate - Reuters","headline":"Boehringer Ingelheim in deal with China's Simcere Pharma to license IBD drug candidate","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMifkFVX3lxTE05R0dLeTA0SnNlbDg1X19MZzlLYmdyVTZUcEJibko4QTQtS3hzZ0dGZXF4NUNLTHhjYUNGWW5FTHRmMmo3blFvSllrOFZsb1pzcHVienZNbzhhSlRjQ1B3MHJjVlVBQmVLYWZMRW9kdGVSb3F3ZGUtbFp1ejR3Zw?oc=5","date":"2026-01-06","type":"pipeline","source":"China Daily","summary":"Simcere eyes growing pharmaceutical niche - China Daily","headline":"Simcere eyes growing pharmaceutical niche","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMingJBVV95cUxQdEFnQktFM210eXdiZmRhVlE4Y3FUTndfak5Cell5OFgyR1Z1QWxsaks4TzU0NTBvZlJIc0o3enpwWTlTYXBFR3o4eFZNZUg2QUpEZGN5Z3ZsTFRqTmZOMVBSZVpoa1YxT3ZHbFlaVVJOZHBWZjFkSE1jSFpXSVVpYVl2U1VhSHRJS1daVHZkSHAtLW5nbW1aeWZIZk9CQUxLNnVlYVF6VVZNRVdtT3ZpVzhMVkI1ODFPLUpqLWpBU3dEVnpWSldBX1JaTmZaX1VTUFJEc0hubWtXZGVwWmw4UmlyLUpTbk5MYVhCRENwaVByRVhzZXhobF9wUGJNYzUtMGNzWEFqbkN3enFKdFplVjJnYzVPQVduMDAzZ1Jn?oc=5","date":"2025-12-08","type":"regulatory","source":"GlobeNewswire","summary":"Eczema Clinical Trial Pipeline Accelerates as 100+ Pharma - GlobeNewswire","headline":"Eczema Clinical Trial Pipeline Accelerates as 100+ Pharma","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMifkFVX3lxTFBGV3lsb3FXNDdYUDF2SjFLRHlwYWswdEdoMG5BRUpOeTFjclBMRjNIWjljUE9XVFUxV0lEeDBxdV9iZy15S0trYWdDTWhuQ2xob1VJLVBPWUdLNHY2RU1nTmtLaElIWkZhcWIyYlJ1bUYzRHlaeDFJZE8wRklLZw?oc=5","date":"2025-10-21","type":"pipeline","source":"China Daily","summary":"Pharma sector transforms for growth - China Daily","headline":"Pharma sector transforms for growth","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijAJBVV95cUxOT3V0UTc3SUE5NDZKYmcxR292V2pYcVhMWjlfaGRfZlpqYTlQYzhRd3RoNXI3N3doZU5ReEVoZmI4RUlBYkM2VWJwNnFWc2xwajk0eWp4RWJvWnZVS1NrRlJuOHlVX1BxQmZPWXMwWFRKWjBpU240ajlrUzNpcWpwR05RMUtycGNUMHZmOHRMWEtNS1NxLUxmNXJxWnlPREhkbThuS0RSSU15cWM5ZUJUam0zd3ZhOGJVaTB3TDl2WTlBMHFKNzZ1NDFpaXNUYzM2LWgtcUl4VHNNbm8yWVc1SVZTT1ota2ZJb3RZVGphY0hOR2FsZ1R5MWs4NVk3MEVYd1dWMk8xSEIwRUZJ?oc=5","date":"2025-04-24","type":"pipeline","source":"PR Newswire","summary":"IBRANCE's Market Growth Marks a Significant Step Forward in Metastatic HR+/HER2− Breast Cancer Treatment Landscape | DelveInsight - PR Newswire","headline":"IBRANCE's Market Growth Marks a Significant Step Forward in Metastatic HR+/HER2− Breast Cancer Treatment Landscape | Del","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipAFBVV95cUxQZ3VIbDZCelllUXMzMUxFdWdkNzV2RzREVGdRR0t5SjRuQnFudW9aSEhVanlLSldoeDcxeXphSTFmRWl5VWF0V1pwVldfQ3cwRFpESmNuVUhvWVZWWUVXWXg1V3BMUndPT3NYR2ZQY0ttVktXYUw1UHlYVGsxZVRYZnJvTVZJMDNNeE5TZ1c4dUY4RWhfSFRZelNfMU0wRmt5dVQ2Tw?oc=5","date":"2024-12-10","type":"pipeline","source":"BioWorld News","summary":"NMPA clears drugs from Innovent/Hutchmed, Hengrui, Henlius, Luye - BioWorld News","headline":"NMPA clears drugs from Innovent/Hutchmed, Hengrui, Henlius, Luye","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiywFBVV95cUxQOHpWQnhoSXdRS1Zza1lNcHdwSm5vWTI1OHlrWTFKdUladkJYZUE3VDVDdl9qa2RFQWxrNVkwYUFFRUw1bVdYRmdEUlhwSkJSSVIyTTVPcTVIaHFndzdFb054Uzd2OF9pTkRSdV9XdU8tV3EzeDFfNWNnVUZpVHRxczJzVy1WcFdza19tMG9ub05MY3pfQkhLNGJiTmpUUkxxTzMwZUFRQ0I4dUVHRW9odmtqOERMTTZzMHJtTUFjSzZzMmxna3hTSmd6bw?oc=5","date":"2024-03-12","type":"regulatory","source":"BioWorld News","summary":"Trispecific antibody SIM-0500 approved for trials in the US and China for multiple myeloma - BioWorld News","headline":"Trispecific antibody SIM-0500 approved for trials in the US and China for multiple myeloma","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMitwFBVV95cUxPN25wOWkzelQzRHE2OERfdDZYNGhCWElLanZmTkZ3Z0h3WmJoLUw5UlQ1c2hZb1RibUJlVTZVQ1hEMWVzS19ja0xyeXhjZUR0ZF9BYUZiYnliUFZRVlR1ZmZOUmtLbjVnbHEyWGw2YTZVd0pFRzNReE5tZFhPTTcySW5qTHp0RjlnakFyV2kyWEs4ME5xT2ZqOVZrbVY3U2M4ZzV0UlhKQVotMl9wdHg0TEdRckZEdFE?oc=5","date":"2023-10-18","type":"deal","source":"BioWorld News","summary":"GI Innovation inks second GI-301 licensing deal with Japan’s Maruho for $220M - BioWorld News","headline":"GI Innovation inks second GI-301 licensing deal with Japan’s Maruho for $220M","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiVkFVX3lxTE9wRkowSVBEcXRDU3dnVU5QRDdnV2c2WnhxamZYOG05YkVIZUZnLTMtdmdyZDhfMUdpRjZlWVVDek5jQU9IMEgxRTlkSXc0TWxqX2NsdG5n?oc=5","date":"2017-05-30","type":"pipeline","source":"Yahoo Finance Australia","summary":"Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (2196.HK) stock price, news, quote and history - Yahoo Finance Australia","headline":"Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (2196.HK) stock price, news, quote and history","sentiment":"neutral"}],"patents":[],"drugCount":18,"phaseCounts":{"phase_3":10,"phase_2":2,"phase_1":5,"marketed":1},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}